Most Read Articles
Pearl Toh, 13 Feb 2017
Atopic dermatitis (AD) during infancy is associated with an increased risk of developing tooth decay by age three, according to results from the GUSTO* study.
02 Aug 2017
Inappropriate prescription of anaerobic antibiotics to intensive care unit (ICU) patients admitted with pneumonia frequently occurs, with the prescription associated with prolonged length of stay (LOS) in the ICU, a study has found.
02 Mar 2017
Levels of the proinflammatory cytokline interleukin-18 (IL-18) appear to be significantly increased in patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection compared with those who have either infection, according to a study.
Pearl Toh, 11 Feb 2017
Lowering the dosage of aminoglycosides guided by therapeutic dose monitoring (TDM) may reduce aminoglycoside-related hearing loss, without compromising its efficacy against multidrug resistant tuberculosis (MDR-TB), a recent study suggests.

Daclatasvir plus asunaprevir effective, tolerable in older and younger genotype 1 HCV patients

04 Apr 2017

Virological response and tolerance with daclatasvir plus asunaprevir therapy appear to be similar between older and younger patients with chronic genotype 1 hepatitis C virus (HCV) infection, a study has shown.

A total of 170 genotype 1 HCV-infected patients in the younger cohort (<75 years) and 139 in the older cohort (≥75 years) received dual therapy with daclatasvir plus asunaprevir for 24 weeks. Efficacy and safety outcomes—virological response and adverse events, respectively—were analysed according to age. The Invader assay facilitated identification of pretreatment resistance-associated variants (RAVs) at NS5A-L31 and NS5A-Y93.

At treatment completion, the sustained virological response (SVR) rate did not differ significantly between the older and younger cohorts (97.1 vs 92.4 percent, respectively). Of note was that all very elderly patients in the cohort (≥85 years; n=19) completed the 24 weeks of treatment and achieved SVR.

On multivariate regression analysis, the absence of prior simeprevir treatment significantly and independently predicted SVR (odds ratio, 56.6; p<0.001).

At a low population frequency (<25 percent), the SVR rate was similar between patients with RAVs and those with no detectable RAVs. The frequency of adverse events was also similar between younger and older patients.

The present data provide evidence of the safety and efficacy of the daclatasvir and asunaprevir dual therapy for older patients with chronic genotype 1 HCV infection, with virological response and tolerance comparable to that of younger patients.

“Even though RAVs were detected, virological response similar to that for patients with no detectable RAVs may still be expected for patients with RAVs as long as the population frequency is low,” researchers said.

Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Feb 2017
Atopic dermatitis (AD) during infancy is associated with an increased risk of developing tooth decay by age three, according to results from the GUSTO* study.
02 Aug 2017
Inappropriate prescription of anaerobic antibiotics to intensive care unit (ICU) patients admitted with pneumonia frequently occurs, with the prescription associated with prolonged length of stay (LOS) in the ICU, a study has found.
02 Mar 2017
Levels of the proinflammatory cytokline interleukin-18 (IL-18) appear to be significantly increased in patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection compared with those who have either infection, according to a study.
Pearl Toh, 11 Feb 2017
Lowering the dosage of aminoglycosides guided by therapeutic dose monitoring (TDM) may reduce aminoglycoside-related hearing loss, without compromising its efficacy against multidrug resistant tuberculosis (MDR-TB), a recent study suggests.